Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Eur J Pediatr Surg ; 11(2): 82-5, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11371041

ABSTRACT

Forty-seven children treated in various Polish centers between 1985 and 1995 for primary malignant liver tumors were retrospectively analyzed. Hepatoblastoma (HB) prevailed--it was found in 39 cases. There were 6 hepatocarcinoma (HCC) cases and 2 cases of undifferentiated sarcoma (UDS). In 44% of HB patients the tumor involved both liver lobes. 18% of children with HB presented with pulmonary metastases at diagnosis. Chemotherapy was applied in 92% of cases (preoperatively in 67%). Tumor resection was performed in 56% of HB patients. Overall survival of patients with hepatoblastoma was 43.6%, while it was 50% for hepatocarcinoma and 100% for undifferentiated sarcoma (2 cases only). Mean observation time was 58 months. The hepatoblastoma subgroup, being the largest (83% of all cases), was analyzed separately for prognostic factors. Completeness of tumor excision strongly influenced survival. Involvement of both lobes of the liver and multifocality of the tumor were other adverse prognostic factors.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatoblastoma/surgery , Liver Neoplasms/surgery , Neoplasms, Germ Cell and Embryonal/surgery , Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/epidemiology , Child , Child, Preschool , Combined Modality Therapy , Female , Hepatoblastoma/drug therapy , Hepatoblastoma/epidemiology , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/epidemiology , Male , Neoplasms, Germ Cell and Embryonal/epidemiology , Poland/epidemiology , Retrospective Studies , Survival Rate
2.
Eur J Pediatr Surg ; 10(5): 300-3, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11194540

ABSTRACT

UNLABELLED: In 4 years (1993-1996) 206 pts. with nephroblastoma were treated. All children were treated according to SIOP 93-01 protocol. Overall survival was 92%. In 27 cases hepatotoxic events occurred. In 10 cases, venoocclusive liver disease (VOD) was diagnosed. VOD is a syndrome associated with hepatomegaly, sudden weight gain or ascites and jaundice. It results from damage to the endothelium of hepatic venules and necrosis of central hepatocytes with subsequent proliferation of fibrous tissue and occlusion of the central hepatic veins. Dactinomycin is one of the drugs considered responsible for its development. Mean age of VOD patients was 4 yrs, however 3 of them were below 1 yr. In all cases, VOD occurred during postoperative chemotherapy (mean 16 th week of treatment). All patients received dactinomycin and vincristine. Five children with right kidney tumors underwent post-operative abdominal irradiation. Main VOD symptoms were hepatomegaly and ascites (80%). Hypertransaminasaemia, as well as, on ultrasound, gallbladder wall thickening and/or free abdominal fluid were observed. Median VOD duration was 27 days and its course was usually temporary and self-limiting. However, in 2 cases recurrent VOD episodes were noted. All children received supportive treatment only. In 6 cases, VOD resulted in chemotherapy delay or drug reductions, while in 4 others chemotherapy was completed preliminarily. Nevertheless it did not affect patients' outcome overall survival in VOD group was 90%. CONCLUSIONS: Total 5% VOD frequency is similar to other reports. Infants and children receiving abdominal irradiation seem to be at special risk of VOD development.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Hepatic Veno-Occlusive Disease/chemically induced , Kidney Neoplasms/drug therapy , Lomustine/adverse effects , Vincristine/adverse effects , Wilms Tumor/drug therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cause of Death , Chemical and Drug Induced Liver Injury/mortality , Chemotherapy, Adjuvant , Child , Child, Preschool , Female , Follow-Up Studies , Hepatic Veno-Occlusive Disease/diagnosis , Hepatic Veno-Occlusive Disease/mortality , Humans , Infant , Infant, Newborn , Kidney Neoplasms/mortality , Lomustine/therapeutic use , Male , Survival Rate , Vincristine/therapeutic use , Wilms Tumor/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...